Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Stock (NVO) Pops as FDA Approves Wegovy Weight Loss Pill
- Closing Bell Movers: Novo Nordisk gains on Wegovy FDA update
- Novo Nordisk says Wegovy pill approved in U.S. as oral GLP-1, Bloomberg reports
- Novo Nordisk says FDA approved Wegovy pill to reduce body weight
- Novo Nordisk up 8% at $51.79 after FDA approval of Wegovy in weight loss